Chelation Partners has developed a chemical “magnet” that removes biologically available iron, making pathogens thousands of times more susceptible to existing antibiotics.
As resistant microbes are rendering traditional classes of antibiotics obsolete, Chelation Partners' technology holds promise to attack pathogens through a novel mechanism—iron deprivation. All infectious microbes have a common, essential and irreplaceable need for iron. They need iron to grow, reproduce and subsequently cause infection. Inadequate supply of iron to infectious microbes cripples their growth and enhances the susceptibility to existing anti-infectives.
Co-administering the Chelation Partner’s chelating agent(s) with an antibiotic allows us to significantly reduce the antibiotic required to achieve the same or better level of control. This means better efficacy at eliminating a microbial infection with a single treatment course. For antibiotics that have toxic side effects or require extended treatment times, it may be possible to significantly improve their side effect profile. More effective elimination also reduces the rate of spread of resistant pathogens. Chelation Partners will change the world of antibiotics by improving efficacy of existing drugs and reviving efficacy of drugs no longer able to treat resistant bacterial strains.
Meet our Team
Bill has over 20 years of experience in a wide variety of biotechnology fields, including vaccines, human genetics, drug development, manufacturing and extensive interactions with the pharmaceutical industry.
Bruce has Ph.D. in microbiology with over 25 years of both academic and industrial experience in life sciences research and development and commercialization of biotechnologies.
Business Executive - CFO
Darrin is a Certified Management Accountant with 20 years of executive financial management and leadership experience with both public and private companies, focusing on strategic planning, acquisitions, financial controls and reporting.